Affimed Retained Earnings (Accumulated Deficit) 2014-2024 | AFMD

Affimed retained earnings (accumulated deficit) from 2014 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Affimed Retained Earnings (Accumulated Deficit) 2014-2024 | AFMD

Affimed retained earnings (accumulated deficit) from 2014 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18.3B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Intra-Cellular Therapies (ITCI)$8.8B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B